Thursday, November 11, 2021
Virtual Poster Session (All Times Pacific)
Nestoras Mathioudakis, MD
Johns Hopkins University, Baltimore, Maryland, USA
Jessica Castle, MD
Oregon Health & Science University, Portland, Oregon, USA
8:30 Outpatient Full Closed-Loop Trial Using An Open-Source Remote Monitoring and Artificial Pancreas Platform
Fabricio Garelli, PhD et al.
Presented by Emilia Fushimi, Eng.
8:34 Significant Reductions in Adverse Events and Hospitalizations with Control-IQ Technology in Adults with Type 1 Diabetes: Data from the CLIO Study
Jordan E. Pinsker, MD et al.
8:38 Impact of Real-World MiniMed™ 670G System Use on Glycemic Outcomes in the United States
Siddharth Arunachalam, MSc et al.
8:42 Real-World Outcomes of the MiniMedTM 780G System when Used with Optimal Settings
Arcelia Arrieta, MS et al.
Presented by Ohad Cohen, MD
8:46 Current Technology Use in Pediatric Patients with Type 1 Diabetes: An Equity-Focused Analysis
Katie Fogle, BS
8:50 Higher Dose of Inhaled Technosphere Insulin Provides Significant Reduction in Post Prandial Glucose Excursions, Without Hypoglycemia
Kevin Kaiserman, MD et al.
8:54 Q&A / Panel Discussion
Julia Mader, MD, PhD
Medical University of Graz, Graz, Austria
Boris Kovatchev, PhD
University of Virginia, Charlottesville, Virginia, USA
9:15 Hyperoptimized DeepLearning Model For Glucose Prediction On DBLG1
Hector Romero-Ugalde, PhD et al.
9:19 Predicting Postprandial Glucose Excursions with Macronutrient Content using an Interpretable Random Forest Augmented by a Digital Twin ODE Model
Rahul Narayan, MS et al.
9:23 In Silico Trial to Quantitatively Measure How Much Different Behavioural Factors Influence Time in Hypoglycemia in Type 1 Diabetes Management
Chiara Roversi, MS et al.
9:27 Importance of Accounting for Correlation Among Noise Samples when Filtering CGM Data: A Simulation Study
Ilaria Siviero, MS et al.
Presented by Nunzio Camerlingo, MSc
9:31 Evaluation of the Safety and Efficacy of the Lalani Insulin Infusion Protocol
Benjamin Lalani et al.
9:35 Generation of Realistic Virtual Diabetes Patients Using a Pix2Pix GAN: In Pursuit of AI-based Diabetes Simulator
Omer Mujahid, MSc et al.
9:39 Q&A / Panel Discussion
Boris Mankovksy, MD, PhD
Institute of Endocrinology, Kiev, Ukraine
Mike McShane, PhD
Texas A&M University, College Station, Texas, USA
10:00 Post-Market Clinical Surveillance of OneTouch Ultra® Plus Blood Glucose Test Strips
Steven Setford, PhD et al.
10:04 Clinical Evaluation of the Lumee™ Glucose System - A Fluorescence-Based long-term continuous glucose sensor
Ulrike Kamecke, Dipl-Ing (FH) et al.
10:08 Wearable Electrochemical Platform for Glucose Monitoring and Diabetes Management
Russell Potts, PhD et al.
10:12 Point-of-Care Insulin Monitoring Using Electrochemical Sensing
Clara Stroh et al.
10:16 1,5-Anhydroglucitol is an Independent Predictor of Mortality in Patients with COVID-19
Eric Button, MS, MBA et al.
10:20 Unsupervised Anomaly Detection Algorithms to Identify Compression Artifacts in Continuous Glucose Monitoring
Elena Idi, MS et al.
10:24 Q&A / Panel Discussion
Hubert Vesper, PhD
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Lori Laffel, MD, MPH
Joslin Diabetes Center Harvard Medical School, Boston, Massachusetts, USA
10:45 Improvements in Hypoglycemia and HbA1c with RT-CGM Adoption: Results from the COACH Study
Stayce Beck, PhD et al.
10:49 Long-Term (7-Year) Glycemic Outcomes with Continuous Glucose Monitoring (CGM) Initiation within First Year of Type 1 Diabetes (T1D) Diagnosis
Anagha Champakanath, MBBS et al.
10:53 Relationship between Time in Range, Glycemic Variability Metrics and Daily Scan Rate in Children with Type 1 Diabetes
Pietro Bosoni, MSc et al.
10:57 A Data-Driven Approach to Predict Carbohydrate Counting Errors in Diabetes Management
Sahaj Shah, BA et al.
11:01 Identifying Patients at High Risk for Cystic Fibrosis Related Diabetes through the use of the Freestyle LibrePro CGM
Jeniece Ilkowitz, RN, MA, CDE et al.
11:05 Upcycling of Used CGM to a Cool Chain Monitor for Insulin
Thomas Wuttke, Dipl.-Ing. et al.
11:09 Q&A / Panel Discussion
Francisco Pasquel, MD, MPH
Emory University, Atlanta, Georgia, USA
Sultan Meo, MD, PhD, FRCP
King Saud University, Riyadh, Saudi Arabia
11:30 Phenolic Preservatives, Present in Commercial Insulins, Trigger Inflammation at Infusion Sites via Mast Cell Activation
Shereen Kesserwan, MS et al.
11:34 Rate of Unexplained Hyperglycemia and Infusion Set Occlusion: Medtronic Extended Infusion Set (EIS) Pivotal Trial and 3-day Infusion Set Study Comparison
Sarnath Chattaraj, PhD et al.
11:38 Potential Cost Savings from a Reduction in Sensor-detected Severe Hypoglycemia Among Users of the InPen Smart Insulin Pen System
Albert Chien, MA, MPH et al.
11:42 User Experiences with an Insulin Pen Platform
April Taylor, MSN, CNS et al.
11:46 Preferences for Connected Insulin Pens: A Discrete Choice Experiment Among Type 1 and Type 2 Diabetes Patients
Rachel S. Newson, PhD et al.
11:50 Determining losses in Jet-Injection Subcutaneous Insulin delivery
Alex McHugh, BE (Hons) et al.
11:54 Q&A / Panel Discussion
Wei-An (Andy) Lee, DO
LAC+USC Medical Center, Los Angeles, California, USA
Jing Wang, PhD, MPH, RN, FAAN
Florida State University, Tallahassee, Florida, USA
12:15 Increased Time-in-Range after Meals When Using the SNAQ App
David Haldimann, MSc et al.
Presented by Aurelian Briner, MA
12:19 Representing Type 1 Diabetes Device Data Using CDISC Standards
John Owen, BSc et al.
Presented by Rebecca Baker, MS, MHA, BSN
12:23 Development of Self-Management Behavior Scores and Profiles with Digital Health Data
Michelle Dugas, PhD et al.
12:27 “Pre-Ramadan” Telemedicine: Effect on Fasting Experience & Glycemic Control during Ramadan in People with Type 1 Diabetes
Sahar Alharthi, MBBS et al.
12:31 The Effects of One Drop Digital Program on Glucose Control in Employees with Type 1 and 2 Diabetes
Lindsay Sears, PhD et al.
12:35 Virtual Care in the COVID-19 Era: Assessing Telemedicine Experiences among Diabetes Care and Education Specialists
Evelyn Cox, BA et al.
12:39 Q&A / Panel Discussion